Please assess the completion status of the following clinical trial:

Trial Title: A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA~* Completion of the 16-week treatment period in the double-blind ASSET study~* Women of childbearing potential must have a negative result on their serum pregnancy test and use reliable methods of contraception during study treatment and for 3 months after study treatment termination.~Reliable methods of contraception are:~1. Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.~2. Intra-uterine devices.~3. Oral, injectable, transdermal or implantable contraceptives only in combination with a barrier method.~Hormone-based contraceptives alone, regardless of the route of administration, are not considered to be reliable methods of contraception.~Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.~Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.~Signed written informed consent is obtained from the patient or patient's parent/ legal representative prior to initiation of any study-related procedure.~EXCLUSION CRITERIA~All patients (Groups A and B):~1. Any major protocol violation in the preceding double-blind ASSET study\*.~2. Hemoglobin concentration less than 6.0 g/dL.~3. Pregnancy or breast-feeding.~   \* Protocol violations will be reviewed by the monitor during site visits and discussed with the study staff on an ongoing basis and at the patient's completion of the double-blind study.~   Group B only:~4. Acute liver disease.~5. Newly diagnosed cirrhosis or portal hypertension.~6. ALT greater than or equal to 3 times ULN and/or albumin greater than 20% below LLN.~7. Newly diagnosed psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).